(Q36429519)

14 August 2017

1 reference

title

Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer (English)

1 reference

14 August 2017

Richard F Riedel

1

1 reference

14 August 2017

Phillip G Febbo

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 August 2005

1 reference

14 August 2017

1 reference

14 August 2017

volume

1

1 reference

14 August 2017

issue

4

1 reference

14 August 2017

page(s)

461-466

1 reference

14 August 2017

cites work

Cancer statistics, 2005

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Interaction of the neu/p185 and EGF receptor tyrosine kinases: implications for cellular transformation and tumor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

The human cancer genome project--one more misstep in the war on cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.1.4.461

21 January 2018

Identifiers

DOI

10.2217/14796694.1.4.461

1 reference

release_st37ht6svvcjtdpyzwdrdoxiwm

14 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/st37ht6svvcjtdpyzwdrdoxiwm

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference